Contents
Therapeutic Areas in Focus
VOLUME 74 AUTUMN 2022
Our brand-new news section covers hot topics from the most important mergers and acquisitions, some significant drug approvals, investigations in the pharma sphere and major news in the world of oncology.
Keep up to date with the biggest news from the pharma world from pages 6 to 11.
Neurology is a key focus topic within this edition, exploring the advances in neurological research, as well as analysing the unmet needs in the field and its future. Many developments have already been made – for example, the use of AI and digital tech – but there is still a long way to go in understanding the needs of patients and in further advancing research techniques.
Rare diseases are difficult to diagnose and treat. As a result, there is constant research and analysis in this area, evident in the largest section of this edition. Rare disease research has long been neglected, in part due to its inherent difficulties. With rare diseases beginning to garner more attention, patient advocacy organisations - a powerful tool for rare diseases researchers - also deserve recognition in this space.
Heart disease is ranked as the largest cause of death worldwide, making research into novel treatments hugely important. Equally important is ensuring equivalent access to medicine and therapies in cardiovascular disease treatment, as vast inequalities have arisen since the COVID-19 pandemic began.
Executive Director – PMGroup Worldwide Ltd - Karl Equi kequi@pmlive.com
Group Managing Editor – PMGroup Worldwide Ltd - Iona Everson IEverson@pmlive.com
Editorial Assistant - Betsy Goodfellow betsy@pharmafile.com
Sales Manager - Eliot Haynes eliot@pharmafile.com
Designer - Peter May designer@samedanltd.com
Pharmafile is published each Spring and Autumn.
For subscription information, please contact us.
The opinions and views expressed by contributors in this book are not necessarily those of the Publisher and, while every care has been taken in the preparation of this book, the Publisher is not responsible for such opinion and views, or for any inaccuracies in the contributions and data it contains.
The Publisher is not responsible for any images or graphics supplied by contributors. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means, without prior permission from Samedan Ltd.
ISSN 0959-8758. All rights reserved. © 2021 Samedan Ltd Cover image: © Unsplash | CDC
For subscription information, please contact us.
The opinions and views expressed by contributors in this book are not necessarily those of the Publisher and, while every care has been taken in the preparation of this book, the Publisher is not responsible for such opinion and views, or for any inaccuracies in the contributions and data it contains.
The Publisher is not responsible for any images or graphics supplied by contributors. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means, without prior permission from Samedan Ltd.
ISSN 0959-8758. All rights reserved. © 2021 Samedan Ltd Cover image: © Unsplash | CDC
Contact us:
Pharmafile, Samedan Ltd, Suite E, 11 BellYard Mews, 175 Bermondsey Street, London SE1 3TN, United Kingdom
T: +44 (0)20 7724 3456
www.pharmafile.com
www.pharmafile.com
